A PHARMACEUTICAL CINDERELLA

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

me market analysts view AZN as a poor stepchild to the major pharmas like Glaxosmithkline. AZN was just never as pretty as its peers, and some analysts applied an across-the-board 10% discount to its valuation. However, S&P did a sharp U-turn three weeks ago following the company’s recent annual business review. So convinced was S&P by the plans of AZN’s senior management that it promptly took AZN from a "sell" to a "buy" overnight. That’s a rare endorsement from a normally skeptical analyst community.

AZN has performed exceptionally well since then, and here’s why I believe it will continue to do so:

AZN is focused on six major therapeutic areas: cardiovascular (CV), gastrointestinal (GI), infection, neuroscience, oncology, and respiratory and inflammation. Like many other pharma majors, it’s also engaged in the research, development, manufacture and marketing of medical devices and implants for use in health care.

In its presentation, AZN outlined how it will grow its top line, better manage costs, and develop its pipeline. AZN’s biggest products like Symbicort, Crestor and Seroquel are AZN’s bread and butter, driving growth across the whole business. These trends should not only continue but also grow over the next five years. All this, despite growing generic competition.

The future also looks bright. Unlike many U.S.-based counterparts, AZN currently has 38 compounds in its pipeline, including late-stage treatments for stroke, heart disease and cancer. And David Brennan, AZN’s chief executive, noted how his company plans to augment its pipeline by a renewed focus on in-house research and development. That also means a commitment to pursuing products and technologies from "external sources," including build a "major international presence" in the research and development of biological therapeutics.

Exclusive  Markets Continue to Grind Upward

What will propel AZN’s stock further upward from here? AZN is using $4.5 billion in free cash to buy back stock and pay dividends (it has a 2.2% yield). This should further support the stock price. More cash, more buybacks, less outstanding stock, higher earnings per share. Simple, really…

Luckily, AZN’s future also comes at a relatively cheap price. It has a lower price earnings to growth (P.E.G) ratio than any of its competitors at 1.71 — putting it at less than half of, say, its embattled U.S. rival, Merck.

So buy AstraZeneca (AZN) at market today, placing your stop at $54.40. For possibly even bigger upside, buy the October $60 call options (AZNJL.X)

PORTFOLIO UPDATE

Mistubishi UFJ (MTU) is up just under 10% since we recommended it three weeks ago, with the options up 50%. Take half your profits here on the options here, but hold on to the rest for even bigger gains.

Cognizant Technologies (CTSH) stock has also jumped about 7%, and the options are up a whopping 57% — an amazing return in this kind of a market. Take half your profits in the options here.

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

The recent sharp correction notwithstanding, Russia has been the second-best performing market in the world this year. But scratch the surface, and you get a different picture.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike Turner’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE